drugset / Trial / NCT07299747
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.
Timeline
- Start
- 2025-12-04
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VBC103 | Unknown | — | — |
Indications
No indication recorded.